Nanjing Well Pharmaceutical Co Ltd (603351) — Cash Flow-to-Debt Ratio
Nanjing Well Pharmaceutical Co Ltd (603351) has a Cash Flow-to-Debt Ratio of 0.08x as of September 2025, meaning its operating cash flow of CN¥69.51 Million could theoretically repay 0% of its total liabilities (CN¥819.31 Million) in one year. Check cash flow reinvestment rate of Nanjing Well Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Nanjing Well Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Nanjing Well Pharmaceutical Co Ltd across 11 annual periods. Also explore Nanjing Well Pharmaceutical Co Ltd total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Nanjing Well Pharmaceutical Co Ltd (2014–2024)
Year-by-year debt coverage analysis for Nanjing Well Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see market cap of Nanjing Well Pharmaceutical Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.33x | CN¥221.79 Million | CN¥672.72 Million | ▲ +88.2% |
| 2023 | 0.18x | CN¥120.24 Million | CN¥686.22 Million | ▲ +5.4% |
| 2022 | 0.17x | CN¥108.99 Million | CN¥655.76 Million | ▲ +757.0% |
| 2021 | -0.03x | CN¥-11.54 Million | CN¥456.01 Million | ▼ -109.1% |
| 2020 | 0.28x | CN¥93.30 Million | CN¥336.75 Million | ▼ -53.6% |
| 2019 | 0.60x | CN¥129.69 Million | CN¥217.06 Million | ▲ +81.4% |
| 2018 | 0.33x | CN¥63.76 Million | CN¥193.59 Million | ▼ -10.9% |
| 2017 | 0.37x | CN¥71.27 Million | CN¥192.73 Million | ▼ -54.9% |
| 2016 | 0.82x | CN¥128.18 Million | CN¥156.25 Million | ▲ +95.2% |
| 2015 | 0.42x | CN¥81.14 Million | CN¥193.01 Million | ▲ +0.8% |
| 2014 | 0.42x | CN¥74.62 Million | CN¥178.94 Million | — |